ABOUT EVENT
Industry’s Definitive Guide to Ophthalmic Delivery
The 3rd Ophthalmic Drug Delivery Summit was an intimate industry-focused forum centred on spearheading ophthalmic device and formulation development. This meeting was your one-stop-shop to gather key updates on cutting-edge technologies, ophthalmic pharmacology and to compare routes of administration capabilities to overcome anatomical barriers, enhance bioavailability, and improve patient outcomes.
Our attendees heard from ophthalmic delivery experts from the likes of Genentech, AbbVie, Bayer, Clearside Biomedical, Ocular Therapeutix, REGENXBIO, Regeneron, Eyepoint Pharmaceuticals and more, and united under one roof to investigate clinical applications of ocular delivery technologies to assess impact on drug efficacy and durability.
You Missed 3 Dynamic Days Of:
 |
Optimizing sustained release formulations and release kinetics to fine-tune dosing for long-lasting retinal delivery with Genentech, Ocular and Alcon |
|
Evaluating the durability and safety of delivering drugs to the retina via suprachoroidal delivery with Everads, Genentech and Clearside |
|
Utilizing gene therapy transduction via sub retinal and para retinal delivery to the retina with REGENXBIO, GelMEDIX and Ray Therapeutics |
|
Troubleshooting species differences and biocompatibility with ocular models to accelerate delivery translation with Genentech and Wake Forest University |
|
Overcoming clinical trial hurdles and achieving operational synergies to streamline development with Aviceda, AbbVie and Regeneron |
Who Attended?
The 3rd Ophthalmic Delivery Summit was created for clinical and preclinical ocular experts, ophthalmic device engineers, product development leaders and formulation specialists.
Hear What Your Peers Had to Say:
“One-stop shop: Focused and high-energy meeting with key ophthalmic drug delivery and development companies’’
Vice President, Clearside
“Small meeting, presentation of really relevant information”
Director, BioCryst
